Anti-CD22-NMS249 is an antibody-drug conjugate (ADC) that targets CD22, comprising the humanized anti-CD22 antibody Pinatuzumab, a cleavable linker (Mc-VC-PAB), and the effective payload of DNA topoisomerase II inhibitor PNU-159682. This compound is utilized in the study of non-Hodgkin lymphoma (NHL).
Molecular Weight:
818.91
Formula:
C41H45F3N8O5S
Target:
Antibody-Drug Conjugates (ADCs)
T9901A-233
* VAT and and shipping costs not included. Errors and price changes excepted